Design Therapeutics, Inc. financial data

Symbol
DSGN on Nasdaq
Industry
Pharmaceutical Preparations
Location
6005 Hidden Valley Road, Suite 110, Carlsbad, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.54K % +25.1%
Debt-to-equity 3.65 % -19.6%
Return On Equity -18 % +23.9%
Return On Assets -17.4 % +23.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 56.6M shares +1.11%
Common Stock, Shares, Outstanding 56.6M shares +1.11%
Entity Public Float 164M USD -56.1%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 56.6M shares +1.13%
Weighted Average Number of Shares Outstanding, Diluted 56.6M shares +1.13%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 43.2M USD -28.4%
General and Administrative Expense 17.6M USD -20.5%
Operating Income (Loss) -60.8M USD +26.3%
Net Income (Loss) Attributable to Parent -47.8M USD +34%
Earnings Per Share, Basic -0.84 USD/shares +35.4%
Earnings Per Share, Diluted -0.84 USD/shares +35.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 30.3M USD +8.54%
Marketable Securities, Current 224M USD -14.9%
Cash, Cash Equivalents, and Short-term Investments 254M USD -12.7%
Other Assets, Current 236K USD
Assets, Current 257M USD -12.7%
Property, Plant and Equipment, Net 1.56M USD -12.3%
Operating Lease, Right-of-Use Asset 2.4M USD -22.8%
Assets 262M USD -12.8%
Accounts Payable, Current 1.47M USD -33.4%
Employee-related Liabilities, Current 2.99M USD -26.5%
Accrued Liabilities, Current 5.96M USD -41.5%
Liabilities, Current 7.43M USD -40%
Operating Lease, Liability, Noncurrent 1.74M USD -30.8%
Liabilities 9.18M USD -38.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 914K USD
Retained Earnings (Accumulated Deficit) -214M USD -28.8%
Stockholders' Equity Attributable to Parent 252M USD -11.4%
Liabilities and Equity 262M USD -12.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.4M USD +28.6%
Net Cash Provided by (Used in) Financing Activities 20M USD
Net Cash Provided by (Used in) Investing Activities 20.6M USD +4.48%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 56.6M shares +1.11%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 8.2M USD +255%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 30.3M USD +8.54%
Deferred Tax Assets, Valuation Allowance 42.4M USD +58.5%
Deferred Tax Assets, Gross 43.4M USD +55.3%
Operating Lease, Liability 2.52M USD -21.7%
Depreciation 143K USD +10.9%
Payments to Acquire Property, Plant, and Equipment 195K USD +124%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -45.6M USD +34.7%
Lessee, Operating Lease, Liability, to be Paid 2.81M USD -24.5%
Property, Plant and Equipment, Gross 3.07M USD +13.6%
Operating Lease, Liability, Current 778K USD +11.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 973K USD +2.96%
Lessee, Operating Lease, Liability, to be Paid, Year One 945K USD +2.94%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 292K USD -42.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 663K USD -31.9%
Deferred Tax Assets, Operating Loss Carryforwards 15.1M USD +23.2%
Unrecognized Tax Benefits 1.8M USD +93.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 663K USD -31.9%
Deferred Tax Assets, Net of Valuation Allowance 975K USD -16.5%
Share-based Payment Arrangement, Expense 12.3M USD -8.3%